Welcome to Markets Desk, your midday read on what's moving markets and why.
Palantir is the name on every trader's lips this afternoon, surging sixteen percent after the data analytics firm posted what management called otherworldly commercial revenue growth in the second quarter. CEO Alex Karp leaned into the AI narrative hard, and institutional buyers responded — this is a stock that's repricing its multiple in real time.
Shifting to pharma, Merck raised its full-year revenue outlook on the strength of newer drug franchises, but simultaneously trimmed profit guidance after booking charges tied to its acquisition of Terns Pharmaceuticals. The market is parsing the two moves carefully — top-line momentum is real, but deal costs are eating into the bottom line, and that tension is keeping the stock from a clean breakout.
And staying in the semiconductor space, Michael Burry appears to have timed his short against the iShares Semiconductor ETF almost perfectly. The fund dropped twenty-one percent through July, validating his long-standing skepticism toward AI-driven chip valuations. Burry has been pressing this trade for months, and last month's rotation out of semis handed him a significant win.
That's the tape. Markets Desk, signing off the floor.
